What is IPSC's current stock price?

IPSC (Century Therapeutics, Inc.) is currently trading at $2.17 with a market cap of $187.9M.

What sector is Century Therapeutics, Inc. in?

Century Therapeutics, Inc. (IPSC) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is IPSC a good stock to buy?

Analysts have a Buy consensus on IPSC with a price target of $3.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

IPSC Century Therapeutics, Inc.

Healthcare

$2.17-3.98%ClosedMarket Cap: $187.9M

As of 2026-05-26

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

0.74

P/S

0.00

EV/EBITDA

-1.94

DCF Value

$2.28

FCF Yield

-49.0%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-53.2%

ROA

-33.0%

ROIC

-37.3%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-21.6M	$—
Q4 null	$0.00	$-19.2M	$—
FY null	$109.2M	$-9.6M	$—
Q3 null	$0.00	$-34.4M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$3.00

Target (Median)

$3.00

Target Range

$2.00 - $4.00

1 Strong Buy2 Buy1 Hold0 Sell0 Strong Sell

HC Wainwright & Co.Buy

2026-04-21

Piper SandlerOverweight

2026-01-20

Leerink PartnersMarket Perform

2025-11-17

Trading Activity

Insider Trades

View All

Pfeiffenberger Brentdirector, officer: President and CEO

SellTue May 19

Carr Douglasofficer: SVP Finance & Operations

SellWed May 06

Murphy Martin Patrickdirector

SellFri Apr 10

Murphy Martin Patrick

SellFri Apr 10

Cowan Chadofficer: Chief Scientific Officer

SellFri Apr 03

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

1.56

Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.

Peers

COEP

CUE